Navigation Links
Chembio Reports 3rd Quarter 2011 Results
Date:11/3/2011

gh the Oswaldo Cruz Foundation (FIOCRUZ) -- During 2010 we received notification from FIOCRUZ that our DPP® HIV 1/2 screening test and our DPP® HIV confirmatory test were each approved by Brazil's National Health Surveillance Agency (ANVISA).  During 2011 our DPP® visceral canine leishmania ("VL") rapid test was approved by Brazil's Ministry of Agriculture, Livestock and Food Supply ("MAPA"). This is the first diagnostic product that FIOCRUZ has successfully submitted for approval to MAPA.  In addition, FIOCRUZ received the required approval from ANVISA for the DPP® Syphilis-Treponemal test and the DPP®-Leptospirosis test.  The submission for the DPP® multiplex Syphilis Treponemal-Non-Treponemal has not yet occurred.

FDA Approval for DPP® HIV 1/2 Screening Assay -- We began submitting the PMA (Pre-Marketing Approval) application using the Modular PMA option, and we have thus far submitted Module I containing manufacturing information and Module II containing non-clinical data, which was submitted in the beginning of October 2011.  We have experienced some delays in completing the clinical trials, which are the main component for the final Module III.  We now expect to finish the clinical trials during the fourth quarter of 2011. As of October 31, 2011 we have completed approximately 90% of the 3,000-patient clinical trials. We believe that the results of the clinical trials thus far indicate that the sensitivity and specificity of this product on all matrices meets or exceeds the performance requirements for FDA approval. However the trials are not complete and there can be no assurance that the FDA will agree with our assessment.  

DPP® Syphilis Screen & Confirm -- We are engaged in a number of activities oriented to commercializing this product.  We have commenced testing at the first of three sites in support of our planned 510(K) clearance of this produ
'/>"/>

SOURCE Chembio Diagnostics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related medicine technology :

1. Chembio to Host Conference Call to Discuss 3rd Quarter 2011 Financial Results
2. Chembio Diagnostics CFO Richard J. Larkin Among the Recipients of "2011 CFO of the Year" Award from Long Island Business News
3. NxStage Reports Record Third Quarter 2011 Financial Results and Raises Revenue Guidance For 2011
4. Savient Pharmaceuticals Reports Third Quarter 2011 Financial Results
5. CVS Caremark Reports Third Quarter Results
6. Onyx Pharmaceuticals Reports Third Quarter 2011 Financial Results
7. Idenix Pharmaceuticals Reports Third Quarter and Nine Month 2011 Financial Results and Provides Pipeline Update
8. Nektar Therapeutics Reports Third Quarter 2011 Financial Results
9. Par Pharmaceutical Companies Reports Third Quarter 2011 Results
10. Luminex Corporation Reports Third Quarter 2011 Results
11. Anthera Pharmaceuticals Reports 2011 Third Quarter Financial Results and Operational Update
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/1/2014)...   Plexus Information Systems, Inc. (Plexus ... Systems (AIMS), announced a partnership with NextGen ... subsidiary of Quality Systems, Inc. and a leading ... Logo - http://photos.prnewswire.com/prnh/20140930/149406 ... This partnership extends the NextGen Healthcare product portfolio ...
(Date:10/1/2014)... NeuroCall, Inc., ("NeuroCall") announced today that it ... Teleneurology services. Dr. Ricardo Garcia-Rivera , Founder and ... proud that our quality of service has been recognized ... lifesaving support and continuity of care to patients of ... the United States ." NeuroCall ...
(Date:10/1/2014)... Oct. 1, 2014 Quantum Materials Corp ... production of photoactive quantum dots for use in ... offering numerous advantages for solar power generation, the ... of quantum dots with which to develop thin ... from commercial utilization and acceptance. The company is ...
Breaking Medicine Technology:Plexus IS' Anesthesia Documentation Solution Strengthens NextGen Healthcare Product Offering 2Plexus IS' Anesthesia Documentation Solution Strengthens NextGen Healthcare Product Offering 3NeuroCall Awarded Joint Commission Accreditation 2Quantum Materials Scaling Up Photoactive Quantum Dot Production for Solar Power Generation 2Quantum Materials Scaling Up Photoactive Quantum Dot Production for Solar Power Generation 3
... Every Four-Week Subcutaneous Golimumab Also Experienced ... and Disease Activity, PARIS, June 11 Findings ... every four-week subcutaneous injections of,golimumab (CNTO 148) 50 mg ... in the signs and symptoms of,rheumatoid arthritis (RA) as ...
... maintenance ... compared to placebo, BRIDGEWATER, N.J., June 10 Sanofi-aventis,announced ... (zolpidem,tartrate extended-release) CIV tablets 12.5 mg provided significant,improvement in sleep ... patients with co-morbid insomnia and major depressive disorder,(MDD) who were ...
Cached Medicine Technology:Data From Two Phase 3 Studies Show Anti-TNF Golimumab Significantly Improved Signs and Symptoms of Rheumatoid Arthritis 2Data From Two Phase 3 Studies Show Anti-TNF Golimumab Significantly Improved Signs and Symptoms of Rheumatoid Arthritis 3Data From Two Phase 3 Studies Show Anti-TNF Golimumab Significantly Improved Signs and Symptoms of Rheumatoid Arthritis 4Data From Two Phase 3 Studies Show Anti-TNF Golimumab Significantly Improved Signs and Symptoms of Rheumatoid Arthritis 5Data From Two Phase 3 Studies Show Anti-TNF Golimumab Significantly Improved Signs and Symptoms of Rheumatoid Arthritis 6Data From Two Phase 3 Studies Show Anti-TNF Golimumab Significantly Improved Signs and Symptoms of Rheumatoid Arthritis 7Data From Two Phase 3 Studies Show Anti-TNF Golimumab Significantly Improved Signs and Symptoms of Rheumatoid Arthritis 8Ambien CR(R) (zolpidem tartrate extended-release) CIV Tablets Improved Insomnia and Daily Functioning in Patients with Co-Morbid Major Depressive Disorder 2Ambien CR(R) (zolpidem tartrate extended-release) CIV Tablets Improved Insomnia and Daily Functioning in Patients with Co-Morbid Major Depressive Disorder 3Ambien CR(R) (zolpidem tartrate extended-release) CIV Tablets Improved Insomnia and Daily Functioning in Patients with Co-Morbid Major Depressive Disorder 4Ambien CR(R) (zolpidem tartrate extended-release) CIV Tablets Improved Insomnia and Daily Functioning in Patients with Co-Morbid Major Depressive Disorder 5
(Date:10/1/2014)... (PRWEB) October 01, 2014 Familylifeinsurancequotes.org ... find life insurance for senior citizens. , Senior ... Agencies will now sell coverage to seniors who are ... can be purchased without taking a medical examination. , ... purchased online and senior clients can qualify. Having life ...
(Date:10/1/2014)... Lifeinsurance-policy.com has released a new blog post ... for smokers. , Smoking will always have a negative ... the best method to find affordable coverage. Insurance brokerage ... coverage. , Whole life insurance premiums will be ... the coverage is permanent, the initial rates are ...
(Date:10/1/2014)... 01, 2014 Farmington Company today ... redefined mission and visual identity helping brokers, consultants ... with them to create greater benefit communication synergies. ... focuses on empowering customers to better leverage Farmington ... crown jewel of the rebrand is the refreshed ...
(Date:10/1/2014)... 2014 Between 23 million and 50 ... according to figures from the National Institutes of Health ... and many of them have something else in common: ... celiac disease. Gluten Free Therapeutics, makers of CeliVites ... celiac disease by publishing a series of blog posts ...
(Date:10/1/2014)... Toronto, Canada (PRWEB) October 01, 2014 ... hair removal and skin rejuvenating destination of choice, is ... run from October through to December. , “We’re doing ... access as possible to our top skin clinic in ... Clinic. “We do so much at Anti Aging Clinic, ...
Breaking Medicine News(10 mins):Health News:Affordable Term Life Insurance - Senior Citizens Can Qualify for Coverage! 2Health News:Affordable Whole Life Insurance Premiums for Smokers! 2Health News:Farmington Company Launches Rebrand and New Positioning 2Health News:Informative New Blog Series Underscores Link Between Celiac Disease and Other Autoimmune Disorders 2Health News:Informative New Blog Series Underscores Link Between Celiac Disease and Other Autoimmune Disorders 3Health News:Anti Aging Clinic, the GTA’s Premier Provider of Anti Aging Treatments, Announces Deal on Units of Botox 2
... LANCASTER, Pa., June 12 Herley Industries,Inc. (Nasdaq: ... third quarter,ended May 4, 2008. Herley reported net sales ... or 13% from the third quarter of the prior,fiscal ... of $0.27 per share including,the impact of a litigation ...
... allow physicians to more accurately diagnose and treat ... University to Syntermed, an Atlanta-based nuclear medicine imaging ... phase analysis (MHPA), a technology developed by Emory ... PhD. , MHPA is designed to quickly and ...
... and molecular machinery is pointing toward new drugs and ... emerging era of personalized medicine, in which doctors aim ... for the right patient, also brings concerns about genetic ... , The American Association for the Advancement of ...
... TULSA, Okla., June 12 Do you know ... those individuals and,organizations working to improve Oklahoma,s health. ... of those who are making a,significant difference in ... the deadline of Friday, Aug. 1., Nominations ...
... Clear Need for Continued Industry Commitment to Health IT Privacy and ... ... June 12 As consumer options for online,health management expand, there ... complex technologies contribute to,better health and added convenience. Wide-spread adoption requires ...
... June 12 Best Practices, LLC,conducted this study ... used by companies across various industries to measure,the ... pharmaceutical industry, number of sales calls is most ... manufacturing,companies employ year over year account revenue growth ...
Cached Medicine News:Health News:Herley Reports Third Quarter Results 2Health News:Herley Reports Third Quarter Results 3Health News:Herley Reports Third Quarter Results 4Health News:Herley Reports Third Quarter Results 5Health News:Herley Reports Third Quarter Results 6Health News:Herley Reports Third Quarter Results 7Health News:Herley Reports Third Quarter Results 8Health News:Herley Reports Third Quarter Results 9Health News:Herley Reports Third Quarter Results 10Health News:Herley Reports Third Quarter Results 11Health News:Herley Reports Third Quarter Results 12Health News:Herley Reports Third Quarter Results 13Health News:Syntermed licenses Emory imaging technology for improved evaluation of heart failure patients 2Health News:AAAS hosts June 20 conference on personalized medicine 2Health News:Nominations Accepted for 2008 'Champions of Health' Awards 2Health News:More Americans Aware of Digital Health Options; Use of Health IT Increases 2Health News:More Americans Aware of Digital Health Options; Use of Health IT Increases 3Health News:More Americans Aware of Digital Health Options; Use of Health IT Increases 4Health News:Benchmarking Study Report on Sales Performance Management 2
... Agilis Steerable Introducer helps physicians ... right or left atrium. With ... tip, and radiopaque tip marker, ... the agility and stability needed ...
... 70 RF Generator introduces maximum ... every day, in every ablation ... and the CARTO EP Navigation ... Catheter provide clinicians with a ...
The Microny pacemakers are among the smallest devices in the world. The Microny II SR+ pacemaker is the world's smallest, single-chamber rate-responsive pulse generator. The Microny pacemakers featur...
... family of pacemakers features several ... truly automatic devices in today's ... unparalleled combination of automated features ... builds on the popular and ...
Medicine Products: